Myasthenia Gravis and Myeloproliferative Neoplasms – Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review

Sasi, Sreethish; Mohamed, Mouhand; P, Chitrambika; Yassin, Mohamed A

doi:10.22541/au.161525501.12600394/v1

Cited by 3 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case, we describe a patient who was found to have a CALR variant (none type 1, none type 2; 2 bp insertion mutation within exon 9) and was presented with an acute STEMI. Our case demonstrates the possibility of thrombosis associated with other CALR mutation variants in ET patients, which remains one of the unmet needs and unanswered questions in MPN, which we attempted to clarify [ 13 - 16 ].…”

Section: Discussionmentioning

confidence: 99%

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Afana¹,

Abu-Tineh²,

Ellahie³

et al. 2023

Cureus

View full text Add to dashboard Cite

Essential thrombocythemia (ET) is one of the classical Philadelphia-negative myeloproliferative neoplasms with different mutations that can be associated with it, like Janus kinase 2 (JAK2), myeloproliferative leukemia protein (MPL), and Calreticulin (CALR) (types 1 and 2). However, there is a lack in the literature concerning other types of CALR mutations and their clinical significance and prognosis. Here we report a 42-year-old male with type 2 diabetes who presented with an inferior ST-elevation myocardial infarction and thrombocytosis. The diagnosis of ET with CALR (neither type 1 nor type 2) was confirmed, which suggests the pathognomonic feature of this mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Afana¹,

Abu-Tineh²,

Ellahie³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Addressing the quality of life and trying to improve it [12,13],as well as answering the unanswered questions and unmet needs in MPNs are patient and hematologist necessity [14,15,16].…”

Section: Case Presentation: -mentioning

confidence: 99%

Effect of Ruxolitinb in refractory pruritus in a patient with high-risk polycythemia vera A Case Report

Karrar

Yassin²

2022

Preprint

View full text Add to dashboard Cite

show abstract

Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Mehra

Varmeziar

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) are prescribed for chronic myeloid leukemia (CML) and some other cancers. The objective was to predict and rank TKI-related adverse events (AEs), including under-reported or preclinical AEs, using novel text mining. First, k-means clustering of 2575 clinical CML TKI abstracts separated TKIs by significant (p < 0.05) AE type: gastrointestinal (bosutinib); edema (imatinib); pulmonary (dasatinib); diabetes (nilotinib); cardiovascular (ponatinib). Next, we propose a novel cross-domain text mining method utilizing a knowledge graph, link prediction, and hub node network analysis to predict new relationships. Cross-domain text mining of 30+ million articles via SemNet predicted and ranked known and novel TKI AEs. Three physiology-based tiers were formed using unsupervised rank aggregation feature importance. Tier 1 ranked in the top 1%: hematology (anemia, neutropenia, thrombocytopenia, hypocellular marrow); glucose (diabetes, insulin resistance, metabolic syndrome); iron (deficiency, overload, metabolism), cardiovascular (hypertension, heart failure, vascular dilation); thyroid (hypothyroidism, hyperthyroidism, parathyroid). Tier 2 ranked in the top 5%: inflammation (chronic inflammatory disorder, autoimmune, periodontitis); kidney (glomerulonephritis, glomerulopathy, toxic nephropathy). Tier 3 ranked in the top 10%: gastrointestinal (bowel regulation, hepatitis, pancreatitis); neuromuscular (autonomia, neuropathy, muscle pain); others (secondary cancers, vitamin deficiency, edema). Results suggest proactive TKI patient AE surveillance levels: regular surveillance for tier 1, infrequent surveillance for tier 2, and symptom-based surveillance for tier 3.

show abstract

Myasthenia Gravis and Myeloproliferative Neoplasms – Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review

Cited by 3 publications

References 34 publications

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Effect of Ruxolitinb in refractory pruritus in a patient with high-risk polycythemia vera A Case Report

Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Contact Info

Product

Resources

About